Skip to main content

Altshuler David's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Feb 3, 2022

Accession no.
0001209191-22-006757
Filed
Feb 3, 2022
Trade date
Feb 1-2, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.17M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Altshuler DavidCIK 0001550395Officer (EVP, Global Research and CSO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 1, 2022Common StockAGrant or awardAcquired+8,166$0.00$041,755Direct
Feb 1, 2022Common StockAGrant or awardAcquired+11,628$0.00$053,383Direct
Feb 1, 2022Common StockAGrant or awardAcquired+12,314$0.00$065,697Direct
Feb 2, 2022Common StockMOption exerciseAcquired+4,660$86.52+$403,183.270,357Direct
Feb 2, 2022Common StockSSaleDisposed−500$247.73F5,F6−$123,86569,857Direct
Feb 2, 2022Common StockSSaleDisposed−127$248.65F6,F7−$31,578.5569,730Direct
Feb 2, 2022Common StockSSaleDisposed−754$249.97F6,F8−$188,477.3868,976Direct
Feb 2, 2022Common StockSSaleDisposed−980$251.22F6,F9−$246,195.667,996Direct
Feb 2, 2022Common StockSSaleDisposed−900$252.10F6,F10−$226,89067,096Direct
Feb 2, 2022Common StockSSaleDisposed−1,099$253.41F6,F11−$278,497.5965,997Direct
Feb 2, 2022Common StockSSaleDisposed−300$254.46F6,F12−$76,33865,697Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 2, 2022Common StockMOption exerciseDisposed−4,660$86.52−$403,183.20Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.35 to $248.34).

Referenced by the price of 1 transaction in Table I.

F6

Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 7 transactions in Table I.

F7

Open market sales reported on this line occurred at a weighted average price of $248.65 (range $248.46 to $249.34).

Referenced by the price of 1 transaction in Table I.

F8

Open market sales reported on this line occurred at a weighted average price of $249.97 (range $249.61 to $250.33).

Referenced by the price of 1 transaction in Table I.

F9

Open market sales reported on this line occurred at a weighted average price of $251.22 (range $250.71 to $251.70).

Referenced by the price of 1 transaction in Table I.

F10

Open market sales reported on this line occurred at a weighted average price of $252.10 (range $251.75 to $252.72).

Referenced by the price of 1 transaction in Table I.

F11

Open market sales reported on this line occurred at a weighted average price of $253.41 (range $253.05 to $253.99).

Referenced by the price of 1 transaction in Table I.

F12

Open market sales reported on this line occurred at a weighted average price of $254.46 (range $254.34 to $254.58).

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)